Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | — | — | — | 0.48 | — | — | — | — | — | — | — | 28.18 | — | 29.50 | 4.06 | 1.31 | 1.30 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +2057.8% | — | — | — | -91.5% | — | — | |
| P/S Ratio | 0.03 | 0.32 | 0.58 | 1.22 | 5.39 | 3.26 | 1.35 | — | 1.83 | 3.99 | 4.02 | 2.91 | 1.12 | 1.16 | 0.89 | 0.90 | 1.18 | 1.05 | 0.34 | 0.31 | 1.06 |
| — | -90.2% | -56.9% | — | +193.6% | -18.4% | -66.5% | — | +63.2% | +244.9% | +351.3% | +225.5% | -4.7% | +10.2% | +158.3% | +191.7% | +11.4% | -18.3% | -68.7% | -88.1% | -18.9% | |
| P/B Ratio | 0.02 | — | — | 1.09 | 2.77 | 1.42 | 0.49 | 2.11 | 0.61 | 0.90 | 1.30 | 0.83 | 0.67 | 1.03 | 1.15 | 1.23 | 1.68 | 1.79 | 0.99 | 0.95 | 0.83 |
| — | — | — | -48.3% | +358.0% | +58.6% | -62.1% | +155.1% | -9.2% | -13.2% | +13.5% | -32.7% | -60.4% | -42.4% | +16.3% | +29.9% | +102.2% | +82.1% | -22.8% | -81.3% | -55.4% | |
| P/FCF | — | — | — | — | — | — | — | 1.61 | — | — | — | — | — | — | — | — | 13.74 | 7.37 | 0.85 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +159.2% | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 8.14 | — | 7.85 | 2.32 | 0.75 | 0.94 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +981.9% | — | — | — | -88.8% | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 23.52 | — | 13.15 | 2.61 | 0.81 | 1.56 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +2788.7% | — | — | — | -91.4% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.9% | 22.4% | 34.9% | 31.5% | -13.9% | 58.9% | 36.8% | -37.2% | -5.2% | -19.2% | -11.9% | -87.3% | 27.8% | 48.8% | 54.5% | 51.7% | 49.5% | 64.3% | 60.3% | 34.2% | 42.0% |
| — | -62.0% | -5.0% | +184.7% | -165.6% | +405.9% | +408.5% | +57.4% | -118.9% | -139.4% | -121.9% | -268.9% | -43.8% | -24.2% | -9.7% | +51.2% | +17.8% | +31.7% | +3.2% | -5.6% | +54.7% | |
| Operating Margin | -415.4% | -261.6% | -545.0% | -730.4% | -539.5% | -312.3% | -256.0% | 586.4% | -252.3% | -316.4% | -228.3% | -324.4% | -77.4% | -35.2% | 4.5% | -23.3% | 8.1% | 36.4% | 34.0% | 30.3% | -38.5% |
| — | +16.2% | -112.9% | -224.5% | -113.9% | +1.3% | -12.1% | +280.8% | -225.8% | -797.7% | -5137.4% | -1291.0% | -1059.6% | -196.8% | -86.7% | -177.0% | +121.0% | +329.4% | +324.9% | +302.3% | -160.8% | |
| Net Margin | -339.3% | -301.8% | -1120.1% | -943.6% | -774.5% | -358.6% | 277.1% | 1383.2% | -209.4% | -248.7% | -172.4% | -250.1% | -61.5% | -26.0% | 2.8% | -11.2% | 4.0% | 25.6% | 26.3% | 23.4% | -42.0% |
| — | +15.8% | -504.1% | -168.2% | -269.9% | -44.2% | +260.8% | +653.1% | -240.7% | -855.6% | -6150.6% | -2133.2% | -1636.5% | -201.7% | -89.2% | -147.8% | +109.5% | +267.7% | +279.8% | +223.8% | -295.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -271.5% | — | -367.2% | -142.7% | -74.8% | -33.1% | 34.6% | -151.1% | -16.0% | -13.8% | -13.3% | -16.5% | -8.9% | -5.8% | 0.9% | -3.7% | 1.4% | 11.1% | 20.0% | 19.8% | -8.3% |
| — | — | -1162.5% | +5.6% | -366.5% | -139.1% | +360.0% | -813.5% | -80.3% | -139.7% | -1593.4% | -345.2% | -724.7% | -152.2% | -95.5% | -118.8% | +117.2% | +498.1% | +497.5% | +315.9% | -119.9% | |
| ROA | -24.0% | -5.3% | -9.0% | -11.8% | -12.7% | -9.7% | 7.0% | -44.3% | -7.1% | -6.7% | -6.9% | -9.5% | -5.6% | -3.7% | 0.6% | -2.6% | 1.0% | 7.5% | 13.2% | 13.1% | -5.3% |
| — | +45.6% | -229.5% | +73.4% | -78.7% | -44.1% | +201.2% | -365.1% | -26.2% | -81.5% | -1245.8% | -261.7% | -669.1% | -149.0% | -95.5% | -120.1% | +118.5% | +536.9% | +630.9% | +464.0% | -131.8% | |
| ROIC | -62.5% | -26.6% | -19.2% | -32.8% | -21.5% | -12.0% | -9.0% | -22.3% | -8.8% | -8.7% | -9.2% | -11.9% | -6.6% | -5.1% | 1.0% | -6.4% | 2.6% | 14.4% | 20.5% | 17.2% | -5.5% |
| — | -121.8% | -112.6% | -47.0% | -143.8% | -38.1% | +1.9% | -87.8% | -32.8% | -69.7% | -984.0% | -85.7% | -359.6% | -135.6% | -94.9% | -137.3% | +146.5% | +627.7% | +494.9% | +520.3% | -18.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.46 | — | — | 2.46 | 1.12 | 0.69 | 0.90 | 3.34 | 0.78 | 0.61 | 0.52 | 0.43 | 0.33 | 0.28 | 0.24 | 0.11 | 0.19 | 0.19 | 0.19 | 0.25 | 0.31 |
| — | — | — | -26.5% | +44.3% | +13.0% | +72.6% | +671.9% | +132.2% | +118.6% | +121.1% | +295.8% | +79.7% | +49.2% | +22.1% | -57.0% | -40.2% | -40.4% | -31.5% | -81.8% | -66.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 6.26 | — | 3.81 | 1.06 | 0.73 | 0.91 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +755.0% | — | — | — | -90.9% | — | — | |
| Current Ratio | 0.06 | 0.05 | 0.06 | 0.06 | 0.14 | 0.96 | 1.03 | 0.95 | 1.47 | 1.58 | 1.88 | 2.28 | 3.04 | 4.02 | 3.32 | 3.78 | 4.21 | 4.20 | 3.67 | 3.95 | 4.42 |
| — | -95.0% | -94.6% | -93.8% | -90.4% | -39.2% | -45.3% | -58.2% | -51.5% | -60.8% | -43.2% | -39.7% | -28.0% | -4.4% | -9.6% | -4.2% | -4.7% | +1.8% | -0.2% | +56.5% | -47.1% | |
| Quick Ratio | 0.06 | 0.05 | 0.05 | 0.06 | 0.14 | 0.93 | 0.98 | 0.92 | 1.33 | 1.44 | 1.73 | 2.10 | 2.73 | 3.75 | 3.08 | 3.54 | 3.92 | 3.93 | 3.43 | 3.65 | 3.56 |
| — | -94.9% | -94.4% | -93.7% | -89.8% | -35.6% | -43.1% | -56.2% | -51.1% | -61.7% | -44.0% | -40.7% | -30.4% | -4.5% | -10.1% | -3.2% | +10.0% | +28.7% | +22.6% | +79.0% | -51.5% | |
| Interest Coverage | -2.37 | -3.34 | -5.11 | -0.88 | -3.52 | -8.52 | -7.68 | -14.44 | -6.85 | -12.13 | -16.15 | -22.61 | -23.67 | -15.89 | 3.62 | -39.22 | 9.84 | 52.80 | 69.28 | 35.61 | -12.44 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRPH stock.
ProPhase Labs, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ProPhase Labs, Inc.'s current operating margin is -415.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ProPhase Labs, Inc.'s business trajectory between earnings reports.